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a b s t r a c t
Background: Homologous cocaine self-administration procedures in laboratory animals and humans may
facilitate translational research for medications development to treat cocaine dependence. This study,
therefore, sought to establish choice between cocaine and an alternative reinforcer in rhesus monkeys
responding under a procedure back-translated from previous human studies and homologous to a human
laboratory procedure described in a companion paper.
Methods: Four rhesus monkeys with chronic indwelling intravenous catheters had access to cocaine
injections (0, 0.043, 0.14, or 0.43 mg/kg/injection) and food (0, 1, 3, or 10 1 g banana-ﬂavored food pellets).
During daily 5 h sessions, a single cocaine dose and a single food-reinforcer magnitude were available in
10 30-min trials. During the initial “sample” trial, the available cocaine and food reinforcer were delivered
non-contingently. During each of the subsequent nine “choice” trials, responding could produce either
the cocaine or food reinforcer under an independent concurrent progressive-ratio schedule.
Results: Preference was governed by the cocaine dose and food-reinforcer magnitude, and increasing
cocaine doses produced dose-dependent increases in cocaine choice at all food-reinforcer magnitudes.
Effects of the candidate medication lisdexamfetamine (0.32–3.2 mg/kg/day) were then examined on
choice between 0.14 mg/kg/injection cocaine and 10 pellets. Under baseline conditions, this reinforcer
pair maintained an average of approximately 6 cocaine and 3 food choices. Lisdexamfetamine dosedependently decreased cocaine choice in all monkeys, but food choice was not signiﬁcantly altered.
Conclusions: These results support utility of this procedure in rhesus monkeys as one component of a
platform for translational research on medications development to treat cocaine use disorder.
© 2016 Elsevier Ireland Ltd. All rights reserved.

1. Introduction
Cocaine use disorder remains a signiﬁcant clinical challenge for
which there are no medications currently approved by the Food and
Drug Administration. Research to evaluate the efﬁcacy and safety
of new medications for drug abuse or other disorders beneﬁts from
a translational path from preclinical to clinical studies, and a key
step along this path occurs at the transition from research in animals to human laboratory studies (Comer et al., 2008; Haney and
Spealman, 2008; Mello and Negus, 1996; Rush and Stoops, 2012).
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0376-8716/© 2016 Elsevier Ireland Ltd. All rights reserved.

A change in species is unavoidable at this transition; however, the
ﬁdelity of translation may beneﬁt from (1) the use of nonhuman
primates as animal subjects due to their high biological similarity
with humans, especially with regard to monoaminergic systems
affected by cocaine and many candidate medications (Weerts et al.,
2007; Bradberry, 2008), and (2) the use of homologous experimental procedures that minimize discrepancies in variables other than
species and maximize potential for direct comparison of results
across species (Czoty et al., 2016b; Foltin et al., 2015; Yu, 2011).
In particular, recent reviews on medications development for drug
abuse research have suggested that translation is optimized by use
of procedures that test effects of medication maintenance on choice
between the abused drug and an alternative non-drug reinforcer
(Haney and Spealman, 2008; Jones and Comer, 2013; Banks et al.,
2015a; Czoty et al., 2016b). Although choice procedures have been
developed for use in both animals and humans, there remain dis-
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crepancies in many procedural details for the most commonly used
approaches (Banks and Negus, 2012; Jones and Comer, 2013). As a
result, the opportunity exists to achieve closer alignment between
preclinical and human laboratory choice procedures as one strategy to facilitate preclinical to clinical translation of results obtained
with those procedures.
As one step to address this opportunity, the goal of this project
and the companion study conducted in humans (Lile et al., 2016)
was to develop homologous drug self-administration procedures
in nonhuman primates and humans as a platform for translational
research on candidate medications to treat drug abuse. In particular, these studies sought to harmonize three sets of procedural
variables: (1) the route and doses of self-administered cocaine,
(2) the schedule of reinforcement that governed availability of
cocaine and an alternative non-drug reinforcer, and (3) the treatment regimen for delivery of a candidate medication. With regard
to the schedule of self-administration, previous human-laboratory
studies have identiﬁed concurrent independent progressive-ratio
schedules of choice between drug and money as a sensitive tool
for medication evaluation (Jones and Comer, 2013; Moeller and
Stoops, 2015; Stoops et al., 2012; Sullivan et al., 2006). Accordingly,
cocaine self-administration was established in rhesus monkeys
and human subjects under nearly identical concurrent independent progressive-ratio schedules of choice between cocaine and
a species-speciﬁc non-drug alternative reinforcer (food in monkeys; money in humans). The cocaine dose and magnitude of the
non-drug alternative were then systematically manipulated in each
species, with the same unit doses of cocaine being used in both
species. Results are reported here for the study in nonhuman primates and in a companion paper for the study in human subjects
(Lile et al., 2016). We hypothesized that comparable patterns of
cocaine choice could be demonstrated in rhesus monkeys and
humans, and that speciﬁc parameters of cocaine dose and alternative reinforcer magnitude could be identiﬁed for subsequent
evaluation of candidate medications in both species.
The present study also evaluated effects of lisdexamfetamine
as a representative candidate medication. Lisdexamfetamine is an
amphetamine prodrug approved for treatment of ADHD and compulsive eating disorder (Blick and Keating, 2007; Hutson et al.,
2014), and it was selected for initial testing because preclinical
and clinical research suggests that it might also be useful for treating cocaine use disorder (Banks et al., 2015b; Mooney et al., 2015).
Furthermore, maintenance on its metabolite, d-amphetamine, has
been shown to decrease cocaine self-administration across a broad
range of experimental conditions in rats, rhesus monkeys, humanlaboratory studies, and placebo-controlled, double-blind clinical
trials (Herin et al., 2010; Negus and Henningﬁeld, 2015; Nuijten
et al., 2016). Each lisdexamfetamine dose was tested using a subchronic, 7-day treatment regimen, because medications to treat
drug use disorders are administered chronically in humans, and
it has been argued that preclinical animal- and human-laboratory
studies should also evaluate effects of repeated treatment delivery to more accurately predict clinical effectiveness (Czoty et al.,
2016b; Banks et al., 2015a; Haney and Spealman, 2008; Mello and
Negus, 1996). We hypothesized that 7-day treatment with lisdexamfetamine would produce a dose-dependent decrease in cocaine
choice and a reciprocal increase in choice of the food alternative in
this concurrent independent progressive-ratio choice procedure.

2. Methods
2.1. Subjects
Studies were conducted in four adult male rhesus monkeys
(Macaca mulatta) with various drug histories. One monkey (M1524)

was experimentally naïve at the start of the study. A second monkey
(M1501) was exposed to two one-month regimens of oxycodone
administration over a period of one year, and these studies terminated 8 months before transfer to choice studies. The third monkey
(M1498) was exposed to three one-month regimens of oxycodone
administration over a period of approximately 16 months. This
monkey was then involved in drug self-administration studies with
phencyclidine (two months) and cocaine (six months), and these
studies terminated one month before transfer to choice studies. The
fourth monkey (M1416) had a history of morphine dependence as a
juvenile, followed by a history of heroin self-administration (three
months), cocaine self-administration (ﬁve months), and cocaine
discrimination (four years) as an adult. These studies terminated
1 month before transfer to choice studies. Monkeys M1498 and
M1416 also received acute exposure to various classes of test drugs,
and all monkeys had intermittent exposure to ketamine as an anesthetic for husbandry procedures.
Each monkey had a surgically implanted venous catheter with
a single lumen (Braintree Inc., Braintree, MA) or double lumen
(STI Components, Roanoke, VA). Monkeys could earn 1 g bananaﬂavored pellets (5TUR Grain-based Precision Primate Pellets; Test
Diets, St. Louis, MO) during daily experimental sessions. In addition,
monkeys received daily food rations (Lab Diet High Fiber Monkey
Biscuits; PMI Feeds, St. Louis, MO), and the biscuit ration size was
individually determined for each monkey to maintain a healthy
body weight. Biscuit rations were delivered in the afternoons after
behavioral sessions to minimize the effects of biscuit availability
and consumption on food-maintained operant responding. Animals also received fresh fruit 7 afternoons per week. Water was
continuously available in each monkey’s home chamber, which also
served as the experimental chamber. A 12 h light/dark cycle was in
effect (lights on from 0600 to 1800 h). Environmental enrichment
(foraging devices, novel treats, movies and music) was also provided after behavioral sessions. Facilities were accredited by the
Association for Assessment and Accreditation of Laboratory Animal
Care. The Institutional Animal Care and Use Committee approved
all experimental protocols.
2.2. Apparatus
Each home cage was equipped with an operant response panel,
which had two response levers with three stimulus lights above
each lever. The lights over the left and right levers were white and
red, respectively. Additionally, the cages were equipped with a pellet dispenser that delivered food pellets to a receptacle within the
cage. The externalized section of the intravenous catheter for drug
self-administration was routed through a jacket and tether system
(Lomir Biomedical, Quebec, Canada) to the rear of the cage and
connected to a peristaltic ﬂuid pump (Cole-Parmer, Chicago, IL).
Catheter patency was periodically evaluated with intravenous (IV)
ketamine (4 mg/kg) administration, and the catheter was considered patent if IV ketamine administration produced overt loss of
muscle tone within 20 s.
2.3. Single alternative training
Initial training for food-maintained responding proceeded in
a series of incremental steps, during which only one lever
and associated stimulus lights were active (the “food-associated
lever,” counterbalanced between monkeys). Under the terminal
progressive-ratio (PR) schedule, daily 5-h behavioral sessions consisted of 10 discrete 30-min trials. The ﬁrst trial was a “sample”
trial, in which subjects received non-contingent delivery of 10 pellets. The remaining 9 trials were “response” trials, in which food
pellets were available under the PR schedule. Stimulus lights were
illuminated over the lever at the start of each trial, and completion

A.R. Johnson et al. / Drug and Alcohol Dependence 165 (2016) 103–110

of the ratio requirement produced food pellet delivery, initiated
a time out (TO) for the remainder of the trial, and incremented
the ratio for the next trial. If a monkey failed to complete the ratio
requirement within 30 min, the trial terminated without reinforcement, the response counter reset to “0,” a 1-min TO period ensued,
and the ratio requirement did not increment for the next trial. The
starting ratio was 200 in 2 monkeys (M1498, M1524) and 400 in
the other 2 monkeys (M1416, M1501), and the increment after
each completed ratio was 100 for all monkeys (i.e., PR values were
200, 300, 400. . .1000 for two monkeys; 400, 500, 600. . .1200 for
the other 2 monkeys). The lower starting ratio was used in two
monkeys because they failed to complete ≥8 trials with higher
starting ratios. Once monkeys reliably completed ≥8 trials for the
10-pellet reinforcer magnitude under the terminal schedule, a pellet magnitude-effect curve was determined at magnitudes of 0, 1,
3 and 10 pellets. During these studies, the designated pellet magnitude was delivered non-contingently during the sample trial of
each daily session, and responding under the PR schedule produced
this pellet magnitude during subsequent response trials. Each pellet
magnitude was presented for a minimum of 7 consecutive days and
until responding stabilized (number of trials completed for the last
3 days within 1 of the running mean, with no increasing or decreasing trends). Responding maintained by 10 pellets was determined
ﬁrst in all monkeys, and the remaining pellet magnitudes were
studied in a mixed order across monkeys.
Once the pellet magnitude-effect curve was completed, an
intravenous catheter was surgically implanted using aseptic procedures, and cocaine training began. The training regimen for cocaine
self-administration was identical to that for food-maintained
responding with the exception that the other lever and associated stimulus lights were active (the “cocaine-associated lever”),
and responding produced intravenous cocaine injections. Training
proceeded until responding maintained by 0.43 mg/kg/injection
cocaine was stable under the same terminal schedule used for food
in that monkey (i.e., starting ratio of 200 in 2 monkeys and 400
in the other 2 monkeys, with an increment of 100 in all monkeys). Subsequently, a cocaine dose-effect curve was determined
at doses of 0, 0.043, 0.14 and 0.43 mg/kg/injection cocaine using
test durations and stability criteria identical to those used for the
pellet magnitude-effect curve. The cocaine doses were selected to
match approximate unit cocaine doses used in the parallel humanlaboratory study (i.e., 0.043, 0.14 and 0.43 mg/kg/injection unit
doses in monkeys are equivalent to doses of 3, 10 and 30 mg for
a 70 kg human subject; Lile et al., 2016). Responding maintained by
0.43 mg/kg/injection was determined ﬁrst in all monkeys, and the
remaining doses were studied in a mixed order across monkeys.
2.4. Cocaine vs. food choice procedure
After determination of magnitude-effect functions for food and
cocaine alone, concurrent-choice studies were initiated to assess
cocaine choice dose-effect curves during concurrent availability of
1, 3 or 10 pellets. Choice session were identical to sessions under
the terminal schedule for food or cocaine alone with the following
exceptions: (1) a single pellet magnitude and a single cocaine dose
were concurrently available, (2) both the food and drug reinforcers
available during that session were delivered non-contingently at
the start of the sample trial, with food delivered ﬁrst, and cocaine
delivered 5 min later, (3) both food- and cocaine-associated levers
were active at the start of each choice trial, and lights above both
levers were illuminated, (4) the ﬁrst response during each trial
locked in choice for that reinforcer during that trial, deactivated
the alternative lever, and extinguished lights above the alternative
lever, and (5) completion of a ratio produced the chosen reinforcer
and incremented the ratio requirement only for that reinforcer in
the next trial. If a monkey failed to complete a ratio requirement
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within 30 min, then the trial terminated without reinforcement,
the response counter reset to “0” for both levers, a 1-min TO period
ensued, the ratio did not increment for either reinforcer for the next
trial, and the trial was counted as an “omission.” Each combination
of pellet magnitude and cocaine dose was in effect for 7 consecutive days, and all cocaine doses were tested in combination with
any given pellet magnitude before proceeding to a different pellet
magnitude. Both the order of cocaine doses within a pellet magnitude and the order of pellet magnitudes were randomized across
monkeys.
2.5. Effects of lisdexamfetamine
Prior to testing lisdexamfetamine, choice performance was ﬁrst
re-established between 0.14 mg/kg/injection cocaine and 10 pellets (see Section 3 for rationale). Each lisdexamfetamine dose (0.32,
1.0, 1.8, and 3.2 mg/kg/day) was tested for 7 consecutive days, and
baseline choice performance was re-established over a period of
at least 4 days between each 7-day lisdexamfetamine dose test.
On test days, lisdexamfetamine was administered by slow IV infusion over a period of 30 min beginning 1 h before the start of the
daily choice session. The order in which lisdexamphetamine doses
were tested was randomized across monkeys. Throughout the
study, including during lisdexamfetamine studies, measurement
of choice variables was supplemented by daily observation of overt
behavior for signs of behavioral toxicity (e.g., abnormal postures or
behaviors, convulsions, reduced consumption of food rations), and
provisions were in place to terminate treatment in the event that
behavioral toxicity was observed. No treatment in this study was
terminated; however, in one monkey, the dose of 1.8 mg/kg/day
lisdexamfetamine was tested before scheduled testing of a higher
dose of 3.2 mg/kg/day, and in this monkey 1.8 mg/kg/day lisdexamfetamine fully suppressed responding. To avoid the potential
for toxicity, 3.2 mg/kg/day lisdexamfetamine was not tested in this
subject.
2.6. Data analysis
The primary dependent variables were the mean numbers of
cocaine choices, food choices, and omissions per session. Data from
the last three days of each test condition were ﬁrst averaged within
a monkey and then averaged across monkeys to generate group
means. Data were analyzed by one- or two-way repeated-measures
ANOVA, as appropriate, and a signiﬁcant ANOVA was followed by
either a Dunnet’s or Holm-Sidak post hoc test. The criterion for
signiﬁcance was p < 0.05. Also, as shown in below in Section 3,
lisdexamfetamine decreased cocaine choices in all monkeys, but
effects on food choice varied across monkeys. Accordingly, selected
individual data with lisdexamfetamine are also shown.
2.7. Drugs
(−)-Cocaine HCl (NIDA, Rockville, MD) and lisdexamfetamine
mesylate (B. E. Blough, Research Triangle Institute) were dissolved
in sterile saline for IV injection.
3. Results
3.1. Responding maintained by food or cocaine alone
Training took an average of 2.5 months to reach the terminal
schedule of food presentation (range = 43–142 days). Food pellets maintained a magnitude-dependent increase in responding
(Fig. 1A). When 0 pellets were available, subjects completed an
average of approximately 1 ratio requirement. As the number of
pellets available increased, subjects increased the number of trials
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Fig. 1. Effects of reinforcer magnitude in units of pellet number (A) or cocaine dose (B) on the number of trials completed during single-alternative training. Each condition
was presented for a minimum of 7 days and until stable responding was observed. All points show mean ± SEM for the ﬁnal 3 days in 4 monkeys. Asterisks (*) indicate
statistical signiﬁcance (p < 0.05) compared to 0 pellets (A) or saline (B).

completed (F3,9 = 17.96, p < 0.001), such that an average of approximately 8 trials were completed when 10 pellets were available.
Cocaine self-administration training took an average of 34 days
to reach the terminal schedule (range = 24–48 days), and cocaine
also maintained a dose-dependent increase in responding (Fig. 1B).
When saline was available, subjects completed an average of
approximately 1 ratio requirement. As the dose of cocaine
increased, the number of trials completed increased (F3,9 = 53.42,
p < 0.0001), such that an average of at least 8 trials was completed
during availability of 0.14 and 0.43 mg/kg/injection cocaine.
3.2. Choice between food and cocaine
Fig. 2 shows the mean numbers of completed cocaine trials,
completed food trials, and omissions during the ﬁnal three days for
each cocaine dose at each pellet magnitude. Data within each panel
were analyzed by two-way ANOVA [cocaine dose (0, 0.043, 0.14 and
0.43 mg/kg/injection) × trial outcome (cocaine choice, food choice,
or omission)], and this analysis revealed a signiﬁcant interaction
at each pellet magnitude (Panel A: F6,18 = 9.03, p < 0.001; Panel B:
F6,18 = 10.82, p < 0.0001; Panel C: F6,18 = 17.02, p < 0.0001). Across
all 3 pellet magnitudes, cocaine maintained a dose-dependent
increase in the number of cocaine trials completed, and doses
of 0.14 and 0.43 mg/kg/injection were always chosen in signiﬁcantly more trials than saline, as denoted by asterisks over open
bars in Fig. 2A–C. Similarly, across all three pellet magnitudes,
the mean number of food trials completed tended to decrease as
cocaine dose increased; however, this trend was signiﬁcant only
during availability of 3 and 10 pellets. Under those conditions,
the number of food choices was higher during concurrent availability of saline than during concurrent availability of 0.14 and
0.43 mg/kg/injection cocaine, as denoted by asterisks over closed
bars in Fig. 2B,C. Omissions tended to be highest when low magnitudes of the food and cocaine reinforcers were concurrently
available (e.g., during concurrent availability of 1 pellet and saline
injections in Fig. 2A), and the mean number of omissions tended
to decrease as cocaine dose increased. This tendency attained signiﬁcance during the availability of 1 pellet, when the number of
omissions was higher during availability of saline than during availability of 0.14 and 0.43 mg/kg/injection cocaine, as denoted by
asterisks over gray bars in Fig. 2A).
The analysis of choice results as shown in Fig. 2 also permitted evaluation of preference between food and cocaine at each
combination of pellet magnitude and cocaine dose (see dollar
signs in Fig. 2A–C). Both 0.14 and 0.43 mg/kg/injection cocaine
were preferred to 1 pellet (Fig. 2A). During availability of 3 pellets, food was preferred to saline injections, whereas 0.14 and
0.43 mg/kg/injection cocaine were preferred to food (Fig. 2B). During availability of 10 pellets, food was preferred to saline and the

lowest dose of 0.043 mg/kg/injection cocaine, whereas the highest dose of 0.43 mg/kg/injection cocaine was preferred to food
(Fig. 2C). During the availability 10 pellets, preference for the
0.14 mg/kg/injection cocaine dose was not signiﬁcant.
3.3. Effects of lisdexamfetamine treatment
Choice between 0.14 mg/kg/injection cocaine and 10 pellets was
selected as the baseline for the experiment with lisdexamfetamine
because (1) it yielded a trend, albeit non-signiﬁcant, toward cocaine
preference (approximately 6 cocaine and 3 food trials completed)
with few omissions, and (2) a reduction in cocaine dose produced
reallocation of choice that resulted in signiﬁcant preference for
this food magnitude, again with few omissions. Thus, behavior
maintained by this pair of reinforcer magnitudes was likely to be
sensitive to reductions in the relative reinforcing efﬁcacy of cocaine
during pharmacological treatment. As a prelude to presentation of
lisdexamfetamine effects, Fig. 3A shows four hypothetical changes
in choice between 0.14 mg/kg/injection cocaine and 10 pellets that
could be observed during candidate medication treatment. Outcome #1 is interpreted as therapeutically desirable and consists of
a decrease in cocaine trials completed with a reciprocal increase
in food trials completed. This outcome indicates a reallocation of
behavior from cocaine choice to food choice and a decrease in the
relative reinforcing efﬁcacy of cocaine in comparison to food. Outcomes #2–4 show three other possible outcomes interpreted as
therapeutically undesirable. Speciﬁcally, outcome #2 shows a concurrent decrease in both cocaine and food trials with an increase
in omissions, suggestive of non-selective behavioral suppression;
outcome #3 shows an increase in completed cocaine trials with a
reciprocal decrease in food trials, suggestive of increased relative
reinforcing efﬁcacy of cocaine; and outcome #4 shows no treatment effect. Of course, graded outcomes between these extremes
are also possible.
Fig. 3B shows choice between 0.14 mg/kg/injection cocaine
and 10 pellets during 7-day treatments with different lisdexamfetamine doses (0, 0.32, 1.0, 1.8, and 3.2 mg/kg/day) Data were
analyzed by two-way ANOVA (trial outcome × lisdexamfetamine
dose), which revealed a signiﬁcant interaction (F6,18 = 4.82,
p < 0.01). Lisdexamfetamine doses of 0.32 and 1.0 mg/kg/day did not
signiﬁcantly alter cocaine or food trials completed or the number
of omissions. A dose of 1.8 mg/kg/day lisdexamfetamine decreased
cocaine trials completed, had no effect on completed food trials,
and increased omissions. The high dose of 3.2 mg/kg/day lisdexamfetamine was tested in only 3 monkeys and produced a proﬁle
of effects similar to 1.8 mg/kg/day lisdexamfetamine.
Lisdexamfetamine time course effects are shown in Supplemental Fig. 1, and saline substitution effects are included
for comparison. Under baseline conditions, preference between
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Fig. 2. Trials completed for either cocaine or food when 1 pellet (A), 3 pellets (B) or 10 pellets (C) was available as the alternative to cocaine (0–0.43 mg/kg/injection). Each
combination of cocaine dose and pellet reinforcer magnitude was available for 7 days. All bars show mean ± SEM for the ﬁnal 3 days in 4 monkeys. Asterisks (*) indicate
statistical signiﬁcance (p < 0.05) within a trial outcome (cocaine choice, food choice, or omission) compared to the 0 cocaine data. Dollar signs ($) indicate statistical signiﬁcance
(p < 0.05) within a cocaine dose between the numbers of cocaine vs. food trials completed.

Individual subject data during 1.8 mg/kg/day lisdexamfetamine
treatment are shown in Supplemental Fig. 2. This dose of lisdexamfetamine decreased the number of completed cocaine trials in
all four monkeys, but the degree to which this decrease in cocaine
choice was accompanied by a reciprocal increase in food choice
varied across monkeys. Monkey 1501 showed full reallocation of
behavior from cocaine to food choice without an increase in omissions. Monkeys 1498 and 1416 showed only partial reallocation of
behavior from cocaine to food choice together with small increases
in omissions. Finally, in Monkey 1524, lisdexamfetamine decreased
both cocaine and food trials completed together with an increase
in omissions. The lower dose of 1.0 mg/kg/day lisdexamfetamine
produced little change in cocaine vs. food choice in this monkey.
There was no clear relationship between individual differences in
sensitivity to lisdexamfetamine and individual differences in other
variables such as drug history or starting ratio.
4. Discussion

Fig. 3. Hypothetical treatment effects (A) or lisdexamfetamine effects (B) on choice
between 0.14 mg/kg/injection cocaine and 10 pellets. The four types of hypothetical outcomes in Panel A are described in text. Panel B shows mean ± SEM
for the ﬁnal 3 days in 4 monkeys (0–1.8 mg/kg/day lisdexamfetamine) or 3 monkeys (3.2 mg/kg/day lisdexamfetamine). Asterisks (*) indicate statistical signiﬁcance
(p < 0.05) within a trial outcome (cocaine choice, food choice, omission) compared
to the 0 lisdexamfetamine treatment dose in Panel B. Dollar signs ($) indicate statistical signiﬁcance (p < 0.05) within a lisdexamfetamine dose between the numbers
of cocaine vs. food trials completed.

0.14 mg/kg/day cocaine and 10 pellets was relatively stable across
all 7 days. Saline substitution decreased the number of trials completed on the cocaine-associated key and produced a reciprocal
increase in food trials completed. This reallocation of behavior was
evident on day 1 and sustained throughout the 7-day experiment.
Lisdexamfetamine produced a dose-and time-dependent decrease
in cocaine trials completed while having smaller and more transient effects on completed food trials. Thus, the decline in cocaine
choice was associated with sustained food choice and an increase
in trial omissions.

The goal of this study was to develop a cocaine-vs.-food choice
procedure in rhesus monkeys homologous to a cocaine-vs.-money
procedure in humans as an experimental tool to facilitate translational research for the development of medications to treat
cocaine use disorder (Lile et al., 2016). There were three main ﬁndings. First, rhesus monkeys could be trained to choose between
cocaine and food under a concurrent progressive-ratio schedule
back-translated from a procedure used in humans to study choice
between cocaine and money. Second, the allocation of behavior between cocaine and food varied systematically as a function
of cocaine dose and food reinforcer magnitude. Moreover, these
results for choice between cocaine and food in monkeys correlated with choice between identical cocaine doses and money in
humans (Lile et al., 2016). Lastly, repeated 7-day treatment with
the candidate medication lisdexamfetamine produced a dose-and
time-dependent decrease in cocaine choice in all monkeys, and did
not signiﬁcantly impact food choice. These results illustrate the
use of the procedure to study a candidate medication and provide
qualiﬁed support for further consideration of lisdexamfetamine
maintenance to treat cocaine use disorder.
4.1. Choice between cocaine and food
This study extends the range of conditions under which cocainevs.-food choice has been established in rhesus monkeys (Banks
and Negus, 2012; Foltin et al., 2015; Nader and Woolverton, 1991;
Negus, 2003; Paronis et al., 2002; Woolverton and Balster, 1981).
Speciﬁcally, this study used a concurrent independent progressiveratio procedure to mimic drug-vs.-money choice procedures used
previously in human laboratory studies in general (Jones and
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Comer, 2013; Moeller and Stoops, 2015; Stoops et al., 2012; Sullivan
et al., 2006) and to match the cocaine-vs.-money choice procedure used in the companion human laboratory study in particular
(Lile et al., 2016). As such, this study represents an example
of back-translation, in which a procedure originally developed
for use in humans was modiﬁed for use in laboratory animals.
Back-translation is one approach that has been used in other disciplines to strengthen the procedural concordance between animal
and human studies and improve the predictive power of forward animal-to-human translational research (Insel et al., 2013;
Keeler and Robbins, 2011). This approach of back-translation has
also been recommended as a strategy to strengthen translational
research on medications development for cocaine abuse (Czoty
et al., 2016b). To our knowledge, this is the ﬁrst demonstration of
cocaine vs. food choice by rhesus monkeys under this type of schedule, although both food and cocaine-maintained responding have
been established separately under progressive-ratio schedules in
rhesus monkeys (Bedford et al., 1978; Negus and Mello, 2003b;
Rowlett et al., 1996; Stafford et al., 1999).
Previous studies have demonstrated that choice between
cocaine and food is sensitive to manipulation of both the cocaine
dose and food-reinforcer magnitude in both rhesus monkeys
(Nader and Woolverton, 1991; Negus, 2003) and rats (Thomsen
et al., 2013). In the present study, similar effects were obtained.
In general, increasing the magnitude of the available cocaine dose
resulted in increased cocaine choice and decreased food choice,
whereas increasing the magnitude of the food reinforcer increased
food choice and decreased cocaine choice. The reciprocal effects
of reinforcer magnitude on preference were especially apparent
when cocaine dose was manipulated during concurrent availability of 10 pellets. Under these conditions, increasing cocaine
doses produced a systematic shift from robust food preference
to robust cocaine preference, and omissions were rare. These
results in the monkey cocaine-vs.-food choice procedure closely
approximate the shift from money preference to cocaine preference
produced by increasing cocaine doses in the human cocaine-vs.money choice procedure described in the companion manuscript
(Lile et al., 2016). This concordance in results from monkey and
human cocaine choice procedures provides one source of evidence
to support predictive validity of these homologous procedures for
translational research on determinants of cocaine choice.
It is also notable that the dose-dependent increases in cocainevs.-food choice in rhesus monkeys observed here and in a previous
study (Foltin et al., 2015) were obtained under discrete-trial procedures that limited the frequency of cocaine injections. These
ﬁndings contrast with a recent report suggesting that cocaine vs.
saccharin preference could be established in rats when intervals
between choice opportunities were short (0 or 1 min) but not
when inter-trial intervals were longer (10 min) (Vandaele et al.,
2015). The reasons for this discrepancy are not clear and may be
related to various procedural differences including species and
identity of the non-drug alternative reinforcer; however, in the
present study using discrete 30-min trials, the highest cocaine dose
(0.43 mg/kg/inj) was preferred to food at all food magnitude alternatives.
4.2. Effects of 7-day lisdexamfetamine treatment on cocaine vs.
food choice
Results of the present study conﬁrm and extend previous
reports that cocaine vs. food choice can be reduced by maintenance either on lisdexamfetamine in rhesus monkeys (Banks
et al., 2015b) or on its primary metabolite amphetamine in rhesus monkeys or rats (Banks et al., 2013; Negus, 2003; Thomsen
et al., 2013). Amphetamine maintenance also decreased cocaine
self-administration maintained under other, non-choice schedules

of reinforcement in rhesus monkeys and rats (Chiodo et al., 2008;
Czoty et al., 2010; Negus and Mello, 2003a, 2003b), as well as
cocaine choice in human laboratory studies and metrics of cocaine
use in clinical trials (Grabowski et al., 2001; Levin et al., 2015;
Nuijten et al., 2016; Rush et al., 2010; Stoops and Rush, 2013). The
present proof-of-concept study used intravenous administration to
permit precise control of the lisdexamfetamine dose, although an
oral formulation is approved for use in humans and would likely be
used in clinical studies. Future translational studies with candidate
medications might beneﬁt from use of the same route of administration for treatment drugs in monkeys and humans to parallel
use of the same route of administration for cocaine (e.g., Czoty
et al., 2016a). Additionally, lisdexamfetamine was administered
here for a duration of 7 days to match anticipated dosing regimens
for human laboratory studies; however, longer treatment regimens
would also be possible in preclinical studies to provide insight on
the longer treatment durations that would be used for clinical trials.
A recent double-blind, placebo-controlled pilot clinical trial
found that lisdexamfetamine maintenance was not signiﬁcantly
better than placebo at reducing cocaine use in a group of 43 cocainedependent individuals (Mooney et al., 2015). However, three
caveats warrant mention in comparing that clinical trial in humans
to the present study in monkeys. First, the highest dose evaluated in
that clinical trial was 70 mg/day, which is approximately equivalent
to the dose of 1 mg/kg/day dose tested in monkeys. Both 70 mg/day
lisdexamfetamine in humans and 1 mg/kg/day lisdexamfetamine in
monkeys produced similar, small and non-signiﬁcant decreases in
metrics of cocaine use. Thus, there was evidence for concordance
in effects produced by similar lisdexamfetamine doses in humans
and monkeys. Second, the authors of the clinical trial appreciated
the impact of regulatory constraints on the doses selected for initial
testing, and they noted that “evaluation of higher doses of lisdexamfetamine may provide clearer evidence of its efﬁcacy in treating
cocaine dependence.” Results of the present study illustrate how
preclinical studies might be useful to address this type of suggestion and inform decisions on whether to pursue testing of higher
doses in humans. Speciﬁcally, the present study found that cocaine
choice was signiﬁcantly reduced by a higher dose of 1.8 mg/kg/day
lisdexamfetamine in monkeys (equivalent to 126 mg/day in a 70 kg
human), and this supports the speculation by the clinical trial
authors that higher lisdexamfetamine doses might also be more
effective to decrease cocaine use in humans. Lastly, the clinical
trial revealed individual differences in some adverse events, in
medication adherence, and in study retention. The present study
also identiﬁed individual differences in undesirable lisdexamfetamine effects in monkeys. Speciﬁcally, although lisdexamfetamine
signiﬁcantly reduced choice of 0.14 mg/kg/inj cocaine doses in all
subjects, the degree to which this decrease in cocaine choice was
accompanied by a reciprocal increase in food choice varied across
subjects. This variability in lisdexamfetamine effectiveness to promote behavioral reallocation to food choice observed in the present
study may be related to the individual differences in the adverse
effects of lisdexamfetamine in humans, which would further support the concordance between non-human primate data using
these procedures and clinical trial results.
The results of the present study with lisdexamfetamine provide
initial evidence for sensitivity of this procedure in rhesus monkeys to effects of a representative candidate medication. As such,
these results provide a preclinical treatment proﬁle that can be
compared to results with other candidate medications as they are
tested in the future. In particular, it would be of interest to identify treatments that not only reduce cocaine choice, but that also
produce a more robust and reliable reallocation of responding to
food choice than was produced here by lisdexamfetamine. Additionally, these results provide an outcome in monkeys that could
be directly compared to results obtained in the complementary
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cocaine-vs.-money choice procedure in humans. A comparison of
treatment effects with lisdexamfetamine and other candidate medications on cocaine choice in rhesus monkeys and humans will be
important for continued validation and reﬁnement of this platform
for translational research.
Conﬂict of interest
There are no relevant conﬂicts of interest to declare. The content
is solely the responsibility of the authors and does not necessarily
represent the ofﬁcial views of the National Institutes of Health. Dr.
Negus has consulted on topics unrelated to this manuscript with
Alkermes, Depomed, and Grunenthal.
Role of funding source
This research and the preparation of this manuscript were supported by grants awarded to Dr. Joshua Lile (National Institute on
Drug Abuse grants K02 DA031766 and R01 DA033364) as well as
a training grant awarded to Virginia Commonwealth University
(NIDA grant T32 DA007027). Additionally, ARJ received a Travel
Award to present this work to the 2015 meeting of the International Study Group Investigating Drugs as Reinforcers (ISGIDAR).
These funding sources had no further role in study design; in the
collection, analysis and interpretation of data; in the writing of the
report; or in the decision to submit the paper for publication.
Contributors
Ms. Johnson and Drs. Banks, Blough, Lile, Nicholson and Negus
designed the study and managed literature searches and summaries of previous related work. Ms. Johnson and Dr. Negus wrote
the protocol and the ﬁrst draft of the manuscript. Ms. Johnson and
Drs. Lile and Negus undertook the statistical analysis and graphical
representation of the data. Ms. Johnson and Drs. Banks, Nicholson
and Negus oversaw conduct of the study. Dr. Blough provided lisdexamfetamine and also provided insights on its pharmacology
relevant to experimental design. All authors contributed to, and
have approved, the ﬁnal manuscript.
Acknowledgement
The authors would like to thank Ellen Soehngen and James Gillespie for technical contributions to the project.
Appendix A. Supplementary data
Supplementary data associated with this article can be found, in
the online version, at http://dx.doi.org/10.1016/j.drugalcdep.2016.
05.021.
References
Banks, M.L., Negus, S.S., 2012. Preclinical determinants of drug choice under
concurrent schedules of drug self-administration. Adv. Pharmacol. Sci., http://
dx.doi.org/10.1155/2012/281768.
Banks, M.L., Blough, B.E., Negus, S.S., 2013. Effects of 14-day treatment with the
schedule III anorectic phendimetrazine on choice between cocaine and food in
rhesus monkeys. Drug Alcohol Depend. 131, 204–213, http://dx.doi.org/10.
1016/j.drugalcdep.2013.05.005.
Banks, M.L., Hutsell, B.A., Schwienteck, K.L., Negus, S.S., 2015a. Use of preclinical
drug vs. food choice procedures to evaluate candidate medications for cocaine
addiciton. Curr. Treat. Options Psychiatry 2, 136–150, http://dx.doi.org/10.
1007/s40501-015-0042-9.
Banks, M.L., Hutsell, B.A., Blough, B.E., Poklis, J.L., Negus, S.S., 2015b. Preclinical
assessment of lisdexamfetamine as an agonist medication candidate for
cocaine addiction: effects in rhesus monkeys trained to discriminate cocaine or
to self-administer cocaine in a cocaine versus food choice procedure. Int. J.
Neuropsychopharmacol. 18, 1–10, http://dx.doi.org/10.1093/ijnp/pyv009.

109

Bedford, J.A., Bailey, L.P., Wilson, M.C., 1978. Cocaine reinforced progressive ratio
performance in the rhesus monkey. Pharmacol. Biochem. Behav. 9, 631–638,
http://dx.doi.org/10.1016/0091-3057(78)90214-9.
Blick, S.K.A., Keating, G.M., 2007. Lisdexamfetamine. Paediatr. Drugs 9, 129–135.
Bradberry, C.W., 2008. Comparison of acute and chronic neurochemical effects of
cocaine and cocaine cues in rhesus monkeys and rodents: focus on striatal and
cortical dopamine systems. Rev. Neurosci. 19, 113–128.
Chiodo, K.A., Läck, C.M., Roberts, D.C.S., 2008. Cocaine self-administration
reinforced on a progressive ratio schedule decreases with continuous
d-amphetamine treatment in rats. Psychopharmacology (Berl.) 200, 465–473,
http://dx.doi.org/10.1007/s00213-008-1222-8.
Comer, S.D., Ashworth, J.B., Foltin, R.W., Johanson, C.E., Zacny, J.P., Walsh, S.L., 2008.
The role of human drug self-administration procedures in the development of
medications. Drug Alcohol Depend. 96, 1–15, http://dx.doi.org/10.1016/j.
drugalcdep.2008.03.001.
Czoty, P.W., Martelle, J.L., Nader, M.A., 2010. Effects of chronic d-amphetamine
administration on the reinforcing strength of cocaine in rhesus monkeys.
Psychopharmacology (Berl.) 209, 375–382, http://dx.doi.org/10.1007/s00213010-1807-x.
Czoty, P.W., Blough, B.E., Fennell, T.R., Snyder, R.W., Nader, M.A., 2016a.
Attenuation of cocaine self-administration by chronic oral phendimetrazine in
rhesus monkeys. Neuroscience 34, 367–376.
Czoty, P.W., Stoops, W.W., Rush, C.R., 2016b. Evaluation of the pipeline for
development of medications for cocaine use disorder: a review of translational
laboratory, human laboratory, and clinical trial research. Pharm. Rev. (in press).
Foltin, R.W., Haney, M., Rubin, E., Reed, S.C., Vadhan, N., Balter, R., Evans, S.M.,
2015. Development of translational preclinical models in substance abuse:
effects of cocaine administration on cocaine choice in humans and non-human
primates. Pharmacol. Biochem. Behav. 134, 12–21, http://dx.doi.org/10.1016/j.
pbb.2015.03.023.
Grabowski, J., Rhoades, H., Schmitz, J., Stotts, A., Daruzska, L.A., Creson, D., Moeller,
F.G., 2001. Dextroamphetamine for cocaine-dependence treatment: a
double-blind randomized clinical trial. J. Clin. Psychopharmacol. 21, 522–526,
http://dx.doi.org/10.1097/00004714-200110000-00010.
Haney, M., Spealman, R., 2008. Controversies in translational research: drug
self-administration. Psychopharmacology (Berl.) 199, 403–419, http://dx.doi.
org/10.1007/s00213-008-1079-x.
Herin, D.V., Rush, C.R., Grabowski, J., 2010. Agonist-like pharmacotherapy for
stimulant dependence: preclinical, human laboratory, and clinical studies.
Ann. N. Y. Acad. Sci. 1187, 76–100, http://dx.doi.org/10.1111/j.1749-6632.
2009.05145.x.
Hutson, P.H., Pennick, M., Secker, R., 2014. Preclinical pharmacokinetics,
pharmacology and toxicology of lisdexamfetamine: a novel d-amphetamine
pro-drug. Neuropharmacology 87, 41–50, http://dx.doi.org/10.1016/j.
neuropharm.2014.02.014.
Insel, T.R., Voon, V., Nye, J.S., Brown, V.J., Altevogt, B.M., Bullmore, E.T., Goodwin,
G.M., Howard, R.J., Kupfer, D.J., Malloch, G., Marston, H.M., Nutt, D.J., Robbins,
T.W., Stahl, S.M., Tricklebank, M.D., Williams, J.H., Sahakian, B.J., 2013.
Innovative solutions to novel drug development in mental health. Neurosci.
Biobehav. Rev. 37, 2438–2444, http://dx.doi.org/10.1016/j.neubiorev.2013.03.
022.
Jones, J.D., Comer, S.D., 2013. A review of human drug self-administration
procedures. Behav. Pharmacol. 24, 384–395, http://dx.doi.org/10.1097/FBP.
0b013e3283641c3d.
Keeler, J.F., Robbins, T.W., 2011. Translating cognition from animals to humans.
Biochem. Pharmacol. 81, 1356–1366, http://dx.doi.org/10.1016/j.bcp.2010.12.
028.
Levin, F.R., Mariani, J.J., Specker, S., Mooney, M., Mahony, A., Brooks, D.J., Babb, D.,
Bai, Y., Eberly, L.E., Nunes, E.V., Grabowski, J., 2015. Extended-release mixed
amphetamine salts vs placebo for comorbid adult
attention-deﬁcit/hyperactivity disorder and cocaine use disorder: a
randomized clinical trial. JAMA Psychiatry 72, 593–602, http://dx.doi.org/10.
1001/jamapsychiatry.2015.41.
Lile, J.A., Stoops, W.W., Rush, C.R., Negus, S.S., Glaser, P.E.A., Hatton, K.W., Hays, L.R.,
2016. Development of a translational model to screen medications for cocaine
use disorder II: choice between intravenous cocaine and money in humans.
Drug Alcohol Depend. (in press).
Mello, N.K., Negus, S.S., 1996. Preclinical evaluation of pharmacotherapies for
treatment of cocaine and opioid abuse using drug self-administration
procedures. Neuropsychopharmacology 6, 375–424, http://dx.doi.org/10.1016/
0893-133X(95)00274-H.
Moeller, S.J., Stoops, W.W., 2015. Cocaine choice procedures in animals, humans,
and treatment-seekers: can we bridge the divide? Pharmacol. Biochem. Behav.
138, 133–141, http://dx.doi.org/10.1016/j.pbb.2015.09.020.
Mooney, M.E., Herin, D.V., Specker, S., Babb, D., Levin, F.R., Grabowski, J., 2015. Pilot
study of the effects of lisdexamfetamine on cocaine use: a randomized,
double-blind, placebo-controlled trial. Drug Alcohol Depend. 153, 94–103,
http://dx.doi.org/10.1016/j.drugalcdep.2015.05.042.
Nader, M.A., Woolverton, W.L., 1991. Effects of increasing the magnitude of an
alternative reinforcer on drug choice in a discrete-trials choice procedure.
Psychopharmacology (Berl.) 105, 169–171.
Negus, S.S., Henningﬁeld, J., 2015. Agonist medications for the treatment of cocaine
use disorder. Neuropsychopharmacology 40, 1815–1825, http://dx.doi.org/10.
1038/npp.2014.322.
Negus, S.S., Mello, N.K., 2003a. Effects of chronic d-amphetamine treatment on
cocaine- and food-maintained responding under a progressive-ratio schedule

110

A.R. Johnson et al. / Drug and Alcohol Dependence 165 (2016) 103–110

in rhesus monkeys. Psychopharmacology (Berl.) 167, 324–332, http://dx.doi.
org/10.1016/S0376-8716(02)00339-3.
Negus, S.S., Mello, N.K., 2003b. Effects of chronic d-amphetamine treatment on
cocaine- and food-maintained responding under a second-order schedule in
rhesus monkeys. Drug Alcohol Depend. 70, 39–52, http://dx.doi.org/10.1016/
S0376-8716(02)00339-3.
Negus, S.S., 2003. Rapid assessment of choice between cocaine and food in rhesus
monkeys: effects of environmental manipulations and treatment with
d-amphetamine and ﬂupenthixol. Neuropsychopharmacology 28, 919–931,
http://dx.doi.org/10.1038/sj.npp.1300096.
Nuijten, M., Blanken, P., vad de Wetering, B., Nuijen, B., van den Brink, W.,
Hendriks, V.M., 2016. Sustained-release desamfetamine in the treatment of
chronic cocaine-dependent patients on heroin-assisted treatment: a
randomised, double-blind, placebo-controlled trial. Lancet (in press).
Paronis, C.A., Gasior, M., Bergman, J., 2002. Effects of cocaine under concurrent
ﬁxed ratio schedules of food and IV drug availability: a novel choice procedure
in monkeys. Psychopharmacology (Berl) 163, 283–291.
Rowlett, J.K., Massey, B.W., Kleven, M.S., Woolverton, W.L., 1996. Parametric
analysis of cocaine self-administration under a progressive- ratio schedule in
rhesus monkeys. Psychopharmacology (Berl.) 125, 361–370.
Rush, C.R., Stoops, W.W., 2012. Agonist replacement therapy for cocaine
dependence: a translational review. Future Med. Chem. 4, 245–265, http://dx.
doi.org/10.4155/fmc.11.184.
Rush, C.R., Stoops, W.W., Sevak, R.J., Hays, L.R., 2010. Cocaine choice in humans
during d-amphetamine maintenance. J. Clin. Psychopharmacol. 30, 152–159,
http://dx.doi.org/10.1097/JCP.0b013e3181d21967.

Stafford, D., LeSage, M., Glowa, J., 1999. Effects of phentermine on responding
maintained by progressive-ratio schedules of cocaine and food delivery in
rhesus monkeys. Behav. Pharmacol. 10, 775–784.
Stoops, W.W., Rush, C.R., 2013. Agonist replacement for stimulant dependence: a
review of clinical research. Curr. Pharm. Des. 19, 7026–7035.
Stoops, W.W., Lile, J.A., Glaser, P.E.A., Hays, L.R., Rush, C.R., 2012. Inﬂuence of acute
bupropion pre-treatment on the effects of intranasal cocaine. Addiction 107,
1140–1147, http://dx.doi.org/10.1111/j.1360-0443.2011.03766.x.
Sullivan, M.A., Vosburg, S.K., Comer, S.D., 2006. Depot naltrexone: antagonism of
the reinforcing, subjective, and physiological effects of heroin.
Psychopharmacology (Berl.) 189, 37–46, http://dx.doi.org/10.1007/s00213006-0509-x.
Thomsen, M., Barrett, A.C., Negus, S.S., Caine, S.B., 2013. Cocaine versus food choice
procedure in rats: environmental manipulations and effects of amphetamine. J.
Exp. Anal. Behav. 99, 211–233, http://dx.doi.org/10.1002/jeab.15.
Vandaele, Y., Cantin, L., Serre, F., Vouillac-Mendoza, C., Ahmed, S.H., 2015. Choosing
under the inﬂuence: a drug-speciﬁc mechanism by which the setting controls
drug choices in rats. Neuropsychopharmacology 41, 646–657, http://dx.doi.
org/10.1038/npp.2015.195.
Weerts, E.M., Fantegrossi, W.E., Goodwin, A.K., 2007. The value of nonhuman
primates in drug abuse research. Exp. Clin. Psychopharmacol. 15, 309–327.
Woolverton, W.L., Balster, R.L., 1981. Effects of antipsychotic compounds in rhesus
monkeys given a choice between cocaine and food. Drug Alcohol Depend. 8,
69–78, http://dx.doi.org/10.1017/CBO9781107415324.004.
Yu, D., 2011. Translational research: current status, challenges and future
strategies. Am. J. Transl. Res. 3, 422–433.

